Sanofi (France)

It’s likely that more companies and universities will add additional assets as time goes on.

The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.

Many people have lost their jobs and, as a result, their insurance. That can be daunting enough, but for those who need life-saving drugs such as insulin, the situation is magnified.

While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.

This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

Biopharma companies from across the globe provide updates on their pipelines and business practices.

The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.

Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.